Vancouver, Canada

Tirosh Shapira

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: The University of British Columbia. Active years: 2026.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tirosh Shapira: Innovator in Antiviral Research

Introduction

Tirosh Shapira is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of antiviral research, particularly through his innovative patent work. His dedication to developing effective antiviral agents showcases his commitment to addressing viral infections.

Latest Patents

Tirosh Shapira holds a patent for "Antiviral agents, uses thereof and methods for their preparation." This patent relates to the use of cladoniamides and their derivatives, such as the compound Formula I, for treating viral infections caused by coronaviruses and flaviviruses. The disclosure also includes methods for the preparation of these antiviral agents, highlighting the potential impact of his work on public health.

Career Highlights

Shapira is affiliated with the University of British Columbia, where he continues to advance his research in antiviral agents. His work is characterized by a strong focus on innovative solutions to combat viral diseases, reflecting his expertise and dedication to the field.

Collaborations

Tirosh Shapira collaborates with François Jean, enhancing the scope and impact of his research endeavors. Their partnership exemplifies the importance of teamwork in scientific innovation.

Conclusion

Tirosh Shapira's contributions to antiviral research through his patent work and collaboration with esteemed colleagues position him as a key figure in the fight against viral infections. His innovative approach and dedication to research continue to inspire advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…